Brief Report: Diminished Gaze Preference for Dynamic Social Interaction Scenes in Youth with Autism Spectrum Disorders / Rebecca C. SHAFFER in Journal of Autism and Developmental Disorders, 47-2 (February 2017)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 47-2 (February 2017) . - p.506-513 Titre : Brief Report: Diminished Gaze Preference for Dynamic Social Interaction Scenes in Youth with Autism Spectrum Disorders Type de document : texte imprimé Auteurs : Rebecca C. SHAFFER, Auteur ; Ernest V. PEDAPATI, Auteur ; Frederick SHIC, Auteur ; Kristina GAIETTO, Auteur ; Katherine BOWERS, Auteur ; Logan K. WINK, Auteur ; Craig ERICKSON, Auteur Article en page(s) : p.506-513 Langues : Anglais (eng) Mots-clés : Eye tracking  Autism spectrum disorder  Social interest  Social impairment  ASD Index. décimale : PER Périodiques Résumé : In this study, we present an eye-tracking paradigm, adapted from previous work with toddlers, for assessing social-interaction looking preferences in youth ages 5–17 with ASD and typically-developing controls (TDC). Videos of children playing together (Social Scenes, SS) were presented side-by-side with animated geometric shapes (GS). Participants with ASD demonstrated reduced SS preferences compared to TDC, results also represented continuously by associations between higher SS preferences and fewer social difficulties across the combined sample. Exploratory analyses identified associations between increased SS preferences and higher Vineland Daily Living Skills in ASD and suggested SS preferences in TDC females might drive ASD versus TDC between-group differences. These findings describe potentially sex-linked couplings between preferences for social information and social functioning in school-aged children. En ligne : http://dx.doi.org/10.1007/s10803-016-2975-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=303 [article] Brief Report: Diminished Gaze Preference for Dynamic Social Interaction Scenes in Youth with Autism Spectrum Disorders [texte imprimé] / Rebecca C. SHAFFER, Auteur ; Ernest V. PEDAPATI, Auteur ; Frederick SHIC, Auteur ; Kristina GAIETTO, Auteur ; Katherine BOWERS, Auteur ; Logan K. WINK, Auteur ; Craig ERICKSON, Auteur . - p.506-513. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 47-2 (February 2017) . - p.506-513 Mots-clés : Eye tracking  Autism spectrum disorder  Social interest  Social impairment  ASD Index. décimale : PER Périodiques Résumé : In this study, we present an eye-tracking paradigm, adapted from previous work with toddlers, for assessing social-interaction looking preferences in youth ages 5–17 with ASD and typically-developing controls (TDC). Videos of children playing together (Social Scenes, SS) were presented side-by-side with animated geometric shapes (GS). Participants with ASD demonstrated reduced SS preferences compared to TDC, results also represented continuously by associations between higher SS preferences and fewer social difficulties across the combined sample. Exploratory analyses identified associations between increased SS preferences and higher Vineland Daily Living Skills in ASD and suggested SS preferences in TDC females might drive ASD versus TDC between-group differences. These findings describe potentially sex-linked couplings between preferences for social information and social functioning in school-aged children. En ligne : http://dx.doi.org/10.1007/s10803-016-2975-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=303

Brief Report: Intranasal Ketamine in Adolescents and Young Adults with Autism Spectrum Disorder-Initial Results of a Randomized, Controlled, Crossover, Pilot Study / Logan K. WINK in Journal of Autism and Developmental Disorders, 51-4 (April 2021)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 51-4 (April 2021) . - p.1392-1399 Titre : Brief Report: Intranasal Ketamine in Adolescents and Young Adults with Autism Spectrum Disorder-Initial Results of a Randomized, Controlled, Crossover, Pilot Study Type de document : texte imprimé Auteurs : Logan K. WINK, Auteur ; Debra L. REISINGER, Auteur ; Paul S. HORN, Auteur ; Rebecca C. SHAFFER, Auteur ; Kaela O'BRIEN, Auteur ; Lauren M. SCHMITT, Auteur ; Kelli R. DOMINICK, Auteur ; Ernest V. PEDAPATI, Auteur ; Craig ERICKSON, Auteur Article en page(s) : p.1392-1399 Langues : Anglais (eng) Mots-clés : Autism  Clinical trial  Ketamine Index. décimale : PER Périodiques Résumé : Dysregulation of glutamate neurotransmission plays a critical role in autism spectrum disorder (ASD) pathophysiology and is a primary target for core deficit research treatment trials. The mechanism of action of ketamine has striking overlap with the theory of ASD as a disorder of synaptic communication and neuronal networks. This two-dose, double-blind, placebo controlled, cross-over pilot trial of intranasal (IN) ketamine targeting core social impairment included individuals with ASD (N = 21) between 14 and 29 years. Participants were randomized to received two doses of IN ketamine (30 and 50 mg) and two doses of matching placebo. No significant impact was noted on the Aberrant Behavior Checklist Social Withdraw subscale. The IN ketamine was well tolerated, with only transient mild adverse effects. En ligne : http://dx.doi.org/10.1007/s10803-020-04542-z Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=445 [article] Brief Report: Intranasal Ketamine in Adolescents and Young Adults with Autism Spectrum Disorder-Initial Results of a Randomized, Controlled, Crossover, Pilot Study [texte imprimé] / Logan K. WINK, Auteur ; Debra L. REISINGER, Auteur ; Paul S. HORN, Auteur ; Rebecca C. SHAFFER, Auteur ; Kaela O'BRIEN, Auteur ; Lauren M. SCHMITT, Auteur ; Kelli R. DOMINICK, Auteur ; Ernest V. PEDAPATI, Auteur ; Craig ERICKSON, Auteur . - p.1392-1399. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 51-4 (April 2021) . - p.1392-1399 Mots-clés : Autism  Clinical trial  Ketamine Index. décimale : PER Périodiques Résumé : Dysregulation of glutamate neurotransmission plays a critical role in autism spectrum disorder (ASD) pathophysiology and is a primary target for core deficit research treatment trials. The mechanism of action of ketamine has striking overlap with the theory of ASD as a disorder of synaptic communication and neuronal networks. This two-dose, double-blind, placebo controlled, cross-over pilot trial of intranasal (IN) ketamine targeting core social impairment included individuals with ASD (N = 21) between 14 and 29 years. Participants were randomized to received two doses of IN ketamine (30 and 50 mg) and two doses of matching placebo. No significant impact was noted on the Aberrant Behavior Checklist Social Withdraw subscale. The IN ketamine was well tolerated, with only transient mild adverse effects. En ligne : http://dx.doi.org/10.1007/s10803-020-04542-z Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=445

Brief Report: Metformin for Antipsychotic-Induced Weight Gain in Youth with Autism Spectrum Disorder / Logan K. WINK in Journal of Autism and Developmental Disorders, 47-7 (July 2017)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 47-7 (July 2017) . - p.2290-2294 Titre : Brief Report: Metformin for Antipsychotic-Induced Weight Gain in Youth with Autism Spectrum Disorder Type de document : texte imprimé Auteurs : Logan K. WINK, Auteur ; Ryan E. ADAMS, Auteur ; Ernest V. PEDAPATI, Auteur ; Kelli C. DOMINICK, Auteur ; Emma FOX, Auteur ; Catherine BUCK, Auteur ; Craig ERICKSON, Auteur Article en page(s) : p.2290-2294 Langues : Anglais (eng) Mots-clés : Autism  Autism spectrum disorder  Metformin  Antipsychotic  Weight gain Index. décimale : PER Périodiques Résumé : Antipsychotic treatment in youth with autism spectrum disorder (ASD) is becoming increasingly common, placing individuals at risk for antipsychotic-induced weight gain and associated complications. Metformin hydrochloride, a biguanide medication FDA-approved for treatment of type-2 diabetes in youth, may hold promise for treatment of antipsychotic-induced weight gain in youth with ASD. In this report we assess the long-term impact of metformin on antipsychotic-associated weight gain in a naturalistic sample of 53 youth with ASD. Results indicate that treatment with metformin stabilized BMI z-score over a nearly 2 year mean treatment period. Further work is indicated to determine the safety and efficacy of metformin treatment in youth with ASD, as well as predictors of response as a treatment for antipsychotic-induced weight gain. En ligne : https://doi.org/10.1007/s10803-017-3132-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=314 [article] Brief Report: Metformin for Antipsychotic-Induced Weight Gain in Youth with Autism Spectrum Disorder [texte imprimé] / Logan K. WINK, Auteur ; Ryan E. ADAMS, Auteur ; Ernest V. PEDAPATI, Auteur ; Kelli C. DOMINICK, Auteur ; Emma FOX, Auteur ; Catherine BUCK, Auteur ; Craig ERICKSON, Auteur . - p.2290-2294. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 47-7 (July 2017) . - p.2290-2294 Mots-clés : Autism  Autism spectrum disorder  Metformin  Antipsychotic  Weight gain Index. décimale : PER Périodiques Résumé : Antipsychotic treatment in youth with autism spectrum disorder (ASD) is becoming increasingly common, placing individuals at risk for antipsychotic-induced weight gain and associated complications. Metformin hydrochloride, a biguanide medication FDA-approved for treatment of type-2 diabetes in youth, may hold promise for treatment of antipsychotic-induced weight gain in youth with ASD. In this report we assess the long-term impact of metformin on antipsychotic-associated weight gain in a naturalistic sample of 53 youth with ASD. Results indicate that treatment with metformin stabilized BMI z-score over a nearly 2 year mean treatment period. Further work is indicated to determine the safety and efficacy of metformin treatment in youth with ASD, as well as predictors of response as a treatment for antipsychotic-induced weight gain. En ligne : https://doi.org/10.1007/s10803-017-3132-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=314

Brief Report: Pilot Single-Blind Placebo Lead-In Study of Acamprosate in Youth with Autistic Disorder / Craig ERICKSON in Journal of Autism and Developmental Disorders, 44-4 (April 2014)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 44-4 (April 2014) . - p.981-987 Titre : Brief Report: Pilot Single-Blind Placebo Lead-In Study of Acamprosate in Youth with Autistic Disorder Type de document : texte imprimé Auteurs : Craig ERICKSON, Auteur ; Logan K. WINK, Auteur ; Maureen C. EARLY, Auteur ; Elizabeth STIEGELMEYER, Auteur ; Lauren MATHIEU-FRASIER, Auteur ; Vanessa PATRICK, Auteur ; Christopher J. MCDOUGLE, Auteur Année de publication : 2014 Article en page(s) : p.981-987 Langues : Anglais (eng) Mots-clés : Acamprosate  Autism spectrum disorder  Glutamate  Gamma-aminobutyric acid Index. décimale : PER Périodiques Résumé : An excitatory/inhibitory (E:I) imbalance marked by enhanced glutamate and deficient gamma-aminobutyric acid (GABA) neurotransmission may contribute to the pathophysiology of autism spectrum disorders (ASD). We report on the first single-blind placebo lead-in trial of acamprosate, a drug with putative mechanisms restoring E:I imbalance, in twelve youth with ASD. We conducted a 12-week single-blind, placebo lead-in study of acamprosate in youth age 5–17 years with autistic disorder. Six of nine subjects who received active drug treatment were deemed treatment responders (defined by a score at final visit of “very much improved” or “much improved” on the Clinical Global Impressions Improvement scale) and ≥25 % improvement on the Aberrant Behavior Checklist Social Withdrawal subscale. Future larger-scale dose finding studies of acamprosate in ASD may be warranted given this preliminary indication of benefit. En ligne : http://dx.doi.org/10.1007/s10803-013-1943-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=228 [article] Brief Report: Pilot Single-Blind Placebo Lead-In Study of Acamprosate in Youth with Autistic Disorder [texte imprimé] / Craig ERICKSON, Auteur ; Logan K. WINK, Auteur ; Maureen C. EARLY, Auteur ; Elizabeth STIEGELMEYER, Auteur ; Lauren MATHIEU-FRASIER, Auteur ; Vanessa PATRICK, Auteur ; Christopher J. MCDOUGLE, Auteur . - 2014 . - p.981-987. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 44-4 (April 2014) . - p.981-987 Mots-clés : Acamprosate  Autism spectrum disorder  Glutamate  Gamma-aminobutyric acid Index. décimale : PER Périodiques Résumé : An excitatory/inhibitory (E:I) imbalance marked by enhanced glutamate and deficient gamma-aminobutyric acid (GABA) neurotransmission may contribute to the pathophysiology of autism spectrum disorders (ASD). We report on the first single-blind placebo lead-in trial of acamprosate, a drug with putative mechanisms restoring E:I imbalance, in twelve youth with ASD. We conducted a 12-week single-blind, placebo lead-in study of acamprosate in youth age 5–17 years with autistic disorder. Six of nine subjects who received active drug treatment were deemed treatment responders (defined by a score at final visit of “very much improved” or “much improved” on the Clinical Global Impressions Improvement scale) and ≥25 % improvement on the Aberrant Behavior Checklist Social Withdrawal subscale. Future larger-scale dose finding studies of acamprosate in ASD may be warranted given this preliminary indication of benefit. En ligne : http://dx.doi.org/10.1007/s10803-013-1943-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=228

Case Report: 16-Year-Old Male with Autistic Disorder with Preoccupation with Female Feet / Maureen C. EARLY in Journal of Autism and Developmental Disorders, 42-6 (June 2012)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 42-6 (June 2012) . - p.1133-1137 Titre : Case Report: 16-Year-Old Male with Autistic Disorder with Preoccupation with Female Feet Type de document : texte imprimé Auteurs : Maureen C. EARLY, Auteur ; Craig ERICKSON, Auteur ; Logan K. WINK, Auteur ; Christopher J. MCDOUGLE, Auteur ; Eric L. SCOTT, Auteur Année de publication : 2012 Article en page(s) : p.1133-1137 Langues : Anglais (eng) Mots-clés : Autism  Female feet  Preoccupation  Exposure therapy  Differential diagnosis  CY-BOCS-PDD Index. décimale : PER Périodiques Résumé : This paper highlights clinical challenges faced when diagnosing and then treating an individual presenting to a child and adolescent psychiatry clinic because of unwelcome comments he made to female peers about their feet. Novel use of exposure therapy helped him effectively decrease his comments from 1 to 2 times per month to once every 6 months. Conceptualizing this case as the individual’s failed attempts toward relationships with females instead of sexual harassment led to diminution of problematic behavior. Implications for diagnosis and treatment of individuals with Autistic Disorder displaying problematic behaviors are presented. En ligne : http://dx.doi.org/10.1007/s10803-011-1340-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=156 [article] Case Report: 16-Year-Old Male with Autistic Disorder with Preoccupation with Female Feet [texte imprimé] / Maureen C. EARLY, Auteur ; Craig ERICKSON, Auteur ; Logan K. WINK, Auteur ; Christopher J. MCDOUGLE, Auteur ; Eric L. SCOTT, Auteur . - 2012 . - p.1133-1137. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 42-6 (June 2012) . - p.1133-1137 Mots-clés : Autism  Female feet  Preoccupation  Exposure therapy  Differential diagnosis  CY-BOCS-PDD Index. décimale : PER Périodiques Résumé : This paper highlights clinical challenges faced when diagnosing and then treating an individual presenting to a child and adolescent psychiatry clinic because of unwelcome comments he made to female peers about their feet. Novel use of exposure therapy helped him effectively decrease his comments from 1 to 2 times per month to once every 6 months. Conceptualizing this case as the individual’s failed attempts toward relationships with females instead of sexual harassment led to diminution of problematic behavior. Implications for diagnosis and treatment of individuals with Autistic Disorder displaying problematic behaviors are presented. En ligne : http://dx.doi.org/10.1007/s10803-011-1340-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=156

Characterization of Medication Use in a Multicenter Sample of Pediatric Inpatients with Autism Spectrum Disorder / Logan K. WINK in Journal of Autism and Developmental Disorders, 48-11 (November 2018)  

Permalink

d-Cycloserine enhances durability of social skills training in autism spectrum disorder / Logan K. WINK in Molecular Autism, 8 (2017)  

Permalink

Developmental milestones and daily living skills in individuals with Angelman syndrome / Anjali SADHWANI in Journal of Neurodevelopmental Disorders, 16 (2024)  

Permalink

Differentiating social preference and social anxiety phenotypes in fragile X syndrome using an eye gaze analysis: a pilot study / Michael P. HONG in Journal of Neurodevelopmental Disorders, 11-1 (December 2019)  

Permalink

Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: A chart review study / Benjamin A. ADLER in Autism, 19-1 (January 2015)  

Permalink

Emotion Regulation Intensive Outpatient Programming: Development, Feasibility, and Acceptability / Rebecca C. SHAFFER in Journal of Autism and Developmental Disorders, 49-2 (February 2019)  

Permalink

Fragile X targeted pharmacotherapy: lessons learned and future directions / Craig ERICKSON in Journal of Neurodevelopmental Disorders, 9-1 (December 2017)  

Permalink

Pediatric Quality of Life Inventory (PedsQL) in Fragile X Syndrome / Sarah E. FITZPATRICK in Journal of Autism and Developmental Disorders, 50-3 (March 2020)  

Permalink

Pharmacologic Interventions for Irritability, Aggression, Agitation and Self-Injurious Behavior in Fragile X Syndrome: An Initial Cross-Sectional Analysis / Eleanor M. ECKERT in Journal of Autism and Developmental Disorders, 49-11 (November 2019)  

Permalink

Phenotypic differences in individuals with autism spectrum disorder born preterm and at term gestation / Katherine BOWERS in Autism, 19-6 (August 2015)  

Permalink

---

1 2 (1 - 15 / 21) Par page : 25 50 100 200